MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the latter’s new investigational programmed cell death 1 (PD-1)/vascular ...

RAHWAY, NJ, USA I 14, 2024 I Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately ...

MEDIA RELEASEAfqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

A PD-1/VEGF bispecific antibody is a type of cancer drug designed to target both the programmed cell death protein 1, or PD-1, on immune cells and vascular endothelial growth factor, or VEGF, on tumor ...

SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Cash balance of $427.2M as of September 30, 2024, expected to fund operations into 2028 Ocular to host a Q3 2024 ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

Diabetic retinopathy is a leading cause of vision loss among adults and often goes unnoticed until it reaches advanced stages ...

in patients who failed therapy with drugs targeting vascular endothelial growth factor (VEGF). Sodhi and his colleagues ...

The study demonstrates that activating the vitamin D receptor (VDR) with calcitriol suppresses cell proliferation in ...

open label phase 2 trial in 27 patients with DME who were previously treated with anti-vascular endothelial growth factor (VEGF) therapy. Each patient in the trial was randomly assigned to receive ...